T C Blevins1, D Dahl2, J Rosenstock3, L L Ilag4, W J Huster4, J S Zielonka4, R K Pollom4, M J Prince4. 1. Texas Diabetes & Endocrinology, Austin, TX, USA. 2. Gemeinschaftspraxis für Innere Medizin und Diabetologie, Hamburg, Germany. 3. Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA. 4. Eli Lilly and Company, Indianapolis, IN, USA.
Abstract
AIMS: To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus®) insulin glargine (IGlar) in patients with type 1 diabetes (T1D). METHODS: This phase III, randomized, open-label, 52-week study enrolled patients with T1D [glycated haemoglobin (HbA1c) ≤11%] being treated with basal (once-daily) and bolus insulin. Patients were randomized to receive once-daily LY IGlar (n = 268) or IGlar (n = 267) in combination with mealtime insulin lispro for 52 weeks. The primary efficacy outcome was to test the non-inferiority (0.4% and then 0.3% margin) of LY IGlar to IGlar as measured by change in HbA1c from baseline to 24 weeks. RESULTS: Both treatment groups had similar and significant (p < 0.001) within-group decreases in mean HbA1c values from baseline. LY IGlar met the non-inferiority criteria compared with IGlar for change in HbA1c from baseline to 24 weeks [-0.35 vs -0.46%, least-squares mean difference 0.108% (95% confidence interval -0.002 to 0.219), p > 0.05]. There were no significant (p > 0.05) treatment differences in other efficacy measures, including proportion of patients reaching HbA1c <7%, daily mean blood glucose, and insulin dose at 24 and 52 weeks. At 52 weeks, similar findings were observed between LY IGlar and IGlar for safety outcomes, including adverse events, allergic reactions, hypoglycaemia, weight change and insulin antibodies. CONCLUSIONS: Both LY IGlar and IGlar, when used in combination with mealtime insulin lispro, provided effective and similar glucose control and similar safety profiles.
RCT Entities:
AIMS: To compare the efficacy and safety of LY2963016insulinglargine (LY IGlar) and the reference product (Lantus®) insulinglargine (IGlar) in patients with type 1 diabetes (T1D). METHODS: This phase III, randomized, open-label, 52-week study enrolled patients with T1D [glycated haemoglobin (HbA1c) ≤11%] being treated with basal (once-daily) and bolus insulin. Patients were randomized to receive once-daily LY IGlar (n = 268) or IGlar (n = 267) in combination with mealtime insulin lispro for 52 weeks. The primary efficacy outcome was to test the non-inferiority (0.4% and then 0.3% margin) of LY IGlar to IGlar as measured by change in HbA1c from baseline to 24 weeks. RESULTS: Both treatment groups had similar and significant (p < 0.001) within-group decreases in mean HbA1c values from baseline. LY IGlar met the non-inferiority criteria compared with IGlar for change in HbA1c from baseline to 24 weeks [-0.35 vs -0.46%, least-squares mean difference 0.108% (95% confidence interval -0.002 to 0.219), p > 0.05]. There were no significant (p > 0.05) treatment differences in other efficacy measures, including proportion of patients reaching HbA1c <7%, daily mean blood glucose, and insulin dose at 24 and 52 weeks. At 52 weeks, similar findings were observed between LY IGlar and IGlar for safety outcomes, including adverse events, allergic reactions, hypoglycaemia, weight change and insulin antibodies. CONCLUSIONS: Both LY IGlar and IGlar, when used in combination with mealtime insulin lispro, provided effective and similar glucose control and similar safety profiles.
Authors: Yazed AlRuthia; Ohud H Bahari; Suliman Alghnam; Ali M Alrumaih; Hassan Asiri; Mohammed Alshammari; Mansour Alhowimel; Hana A Al-Abdulkarim Journal: Front Public Health Date: 2022-06-13
Authors: L L Ilag; M A Deeg; T Costigan; P Hollander; T C Blevins; S V Edelman; R J Konrad; R A Ortmann; R K Pollom; W J Huster; J S Zielonka; M J Prince Journal: Diabetes Obes Metab Date: 2016-01-08 Impact factor: 6.577
Authors: Helle Linnebjerg; Eric Chen Quin Lam; Xin Zhang; Mary E Seger; David Coutant; Laiyi Chua; Christoph Kapitza; Tim Heise Journal: Diabetes Obes Metab Date: 2016-09-08 Impact factor: 6.577
Authors: Liza L Ilag; Timothy M Costigan; Mark A Deeg; Robyn K Pollom; Curtis L Chang; Robert J Konrad; Melvin J Prince Journal: Diabetes Ther Date: 2017-03-30 Impact factor: 2.945